Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
Primary Industries
- Drugs
- Pharmaceuticals
- Therapeutic
- Disease
- Alzheimer’s disease
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 29371
License Grant
The Licensee has a worldwide exclusive License to intellectual property relating to ELND005 (AZD-103) with the undisclosed Licensor, an Alzheimer’s disease researcher at the University of Toronto.
License Property
ELND005 (formerly known as AZD-103), scyllo-inositol, is being investigated as an orally administered treatment for Alzheimer's disease (AD). ELND005 may prevent or inhibit the build up of amyloidal protein in the brains of Alzheimer's disease patients.
Field of Use
The rights granted apply to the healthcare industry.
IPSCIO Record ID: 1268
License Grant
The Licensor today announced that the Company and the Licensee have mutually agreed to modify their collaboration Agreement for the development and commercialization of ELND005.
License Property
Based on studies in preclinical models of Alzheimer’s disease, ELND005 is believed to inhibit the aggregation (clumping) of amyloid-beta proteins in the brain thereby neutralizing the toxic effects of these aggregates on nerve cell membranes (synapses). The toxic effects of amyloid-beta proteins include inhibition of nerve cell function and eventually death of nerve cells (neurons), resulting in memory loss and ultimately the dementia that is characteristic of Alzheimer’s disease (AD). The safety and pharmacokinetics of ELND005 were evaluated in a total of 9 Phase 1 studies in 161 healthy volunteers, including healthy elderly subjects. ELND005 has also been evaluated in a completed Phase 2 study in mild to moderate Alzheimer’s patients and an open-label extension of this Phase 2 study is currently ongoing.
ELND005 received fast track designation from the U.S. Food and Drug Administration (FDA) in 2007 for treatment of Alzheimer’s disease. Fast track designation can facilitate development and may expedite regulatory review of drugs that the FDA recognizes as potentially addressing an unmet medical need for serious or life-threatening conditions.
IPSCIO Record ID: 1264
License Grant
The Company has a worldwide exclusive license to intellectual property relating to compounds acquired in connection with an acquisition.
License Property
Compounds Alzheimer's disease compound ELND005 (AZD-103), TT-301 and TT-302 which are anti-inflammatory compounds.
Field of Use
The Field of Use applies to the medical industry.
IPSCIO Record ID: 262864
License Grant
Under the collaboration agreement, the German Company grants the partner an exclusive license to certain therapeutic antibodies for specific targets and receives license fees, research and development funding, milestone payments and/or, if a product is approved for marketing, sales royalties in return. Through the Partnered Discovery Program, the Company generates antibody candidates for partners in the pharmaceutical and biotechnology industries. A HuCAL antibody targeting amyloid beta that is in phase 3 clinical testing by our partner for the treatment of Alzheimer’s disease is Gantenerumab.
License Property
Gantenerumab is a HuCAL antibody directed against amyloid beta (Aß) that is being developed for the treatment of Alzheimer’s disease. Aß denotes a group of peptides that are crucially involved in Alzheimer’s disease as the main component of the amyloid plaques found in the brains of Alzheimer’s patients. In phase 1 clinical trials, gantenerumab has been shown to reduce brain amyloid in mild-to-moderate Alzheimer’s disease patients. Gantenerumab is being investigated in several clinical studies to see if there is a positive effect from intervening at an early stage in the disease’s progression.
Field of Use
Gantenerumab is an investigational immunotherapy being developed to treat Alzheimer’s disease by potentially reducing beta-amyloid plaques in the brain.
IPSCIO Record ID: 3277
License Grant
The Licensor has transferred all of its ELND005 rights and assets to Irish Subsidiary. The Licensee has acquired Irish Subsidiary, which is now a 100% wholly-owned, subsidiary of the Licensee. In parallel with this acquisition, going forward, Irish Subsidiary will be responsible for all future development and commercialization activities of the ELND005 drug candidate.
License Property
ELND005 is an oral drug candidate that is being evaluated in three studies a Phase 2 study for Agitation and Aggression in Alzheimer's Disease, a Phase 2 study for Bipolar Disorder and a Phase 2A study in Down Syndrome. It has been shown to have an acceptable safety profile in six clinical studies and reduced the emergence of multiple neuropsychiatric effects including agitation, aggression, depression and anxiety in a Phase 2 clinical study.
IPSCIO Record ID: 1626
License Grant
The Company entered into an agreement, as amended, with the Irish University granting the Company an exclusive license for drugs/compounds to half the onset and/or progression of neurodegenerative diseases, in general, and Alzheimer’s Disease, in particular.
Field of Use
The Licensee is in the business of researching, developing and marketing cardiovascular and neurobiology products for commercial development relating to the healthcare industry.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
